The effect of endostatin in patients with coronary artery disease (CAD) has been characterized by research that revealed a significant upregulation of endostatin protein levels in the ischemic heart, which was correlated with diminished angiogenesis and the formation of poorly developed collaterals [39,40] (Figure 1). The gene discussed is COL18A1; the disease is benign neoplasm.